ABBV Stock vs. Eli Lilly & Merck

Core Insights - AbbVie stock (NYSE: ABBV) experienced an 11% rally in one week, primarily due to Pfizer's agreement to lower drug prices for Medicaid and a White House decision to grant a three-year exemption from 100% import tariffs, which is viewed positively for the pharmaceutical sector [3] - AbbVie has seen a 15.3% increase in stock price over the past month, prompting comparisons with peers to assess its performance, valuation, and financial metrics [6] Company Overview - AbbVie develops pharmaceuticals for autoimmune diseases, plaque psoriasis, pancreatic insufficiency, and hypothyroidism, focusing on innovative drug development and manufacturing in the United States [4] Performance Metrics - AbbVie's operating margin stands at 23.5%, which is lower than competitors like Eli Lilly (LLY) at 43.0% [8] - AbbVie's revenue growth over the past year is 6.1%, which is moderate and surpasses Merck (MRK), Gilead (GILD), and Bristol-Myers Squibb (BMY), but is below LLY and Amgen (AMGN) [8] - Over the last year, AbbVie's stock has increased by 28.5% and is currently trading at a price-to-earnings (PE) ratio of 114.8, although competitors like GILD have shown higher returns [8]